Onconova Therapeutics Inc... (ONTX)
NASDAQ: ONTX
· Real-Time Price · USD
1.00
0.00 (0.00%)
At close: Apr 02, 2024, 10:00 PM
Onconova Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -166,481.1B | -166,501.6B | -166,523.1B | -141.34M | -18.16M | -18.95M | -20.18M | -20.84M | -20.62M | -18.96M | -17.31M | -15.36M | -15.57M | -16.16M | -18.83M | -21.62M | -24.78M |
Depreciation & Amortization | 12B | 12B | 12B | 15K | 17K | 16K | 16K | 14K | 14K | 14K | 14K | 14K | 14K | 14K | 14K | 15K | 13K |
Stock-Based Compensation | 1,390.4B | 1,390.2B | 1,390B | 1.42M | 1.3M | 1.3M | 1.3M | 1.24M | 1.21M | 1.17M | 1.1M | 988K | 807K | 576K | 409K | 309K | 341K |
Other Working Capital | 1.47M | 1.33M | 1.28M | -1.17M | -1.97M | -2.07M | -916K | 689K | 1.06M | 382K | -777K | -1.45M | -1.15M | -364K | -365K | -185K | 729K |
Other Non-Cash Items | 135,269.8B | 135,302B | 135,028.1B | -300.89B | -301B | -301B | 1,484B | 1,484B | 1,484B | 1,484B | -3,914B | -3,914B | -3,914B | -3,914B | -6.6M | -6.12M | -5.64M |
Deferred Income Tax | 2.26M | 2.26M | 778K | 706K | -706K | n/a | -1,484B | -1,484B | -1,484B | -1,484B | 3,914B | 3,914B | 3,914B | 3,914B | 6.42M | 6.42M | 6.42M |
Change in Working Capital | 1.39M | 1.04M | 455K | -95K | -972K | -301K | 1.48M | 2.77M | 2.85M | 1.48M | -484K | -2.15M | -1.43M | -3.59M | -2.11M | -1.19M | 385K |
Operating Cash Flow | -29,808.9B | -29,797.4B | -29,792B | -30.22M | -17.81M | -17.93M | -17.39M | -16.82M | -16.54M | -16.29M | -16.68M | -17.04M | -17.14M | -19.49M | -20.69M | -22.19M | -23.26M |
Capital Expenditures | 28B | 28B | 14B | -14K | -14B | -14B | -14K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -15K | -30K | -45K |
Cash Acquisitions | -3,648B | -3,648B | -3,648B | -3.65M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | 19,977B | 19,977B | 19,977B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -19,977B | -19,977B | -19,977B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 15K | 15K | 15K |
Investing Cash Flow | -3,620B | -3,620B | -3,634B | -3.66M | -14B | -14B | -14K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 15K | n/a | -15K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 19,980.1B | 19,977B | 19,977B | 14M | n/a | n/a | n/a | n/a | n/a | n/a | -35K | 19.91M | 19.92M | 55.56M | 55.87M | 38.65M | 40.22M |
Financial Cash Flow | 33,979.1B | 33,976B | 33,976B | 14M | n/a | n/a | n/a | n/a | n/a | n/a | -35K | 19.91M | 19.92M | 55.56M | 55.87M | 38.65M | 40.22M |
Net Cash Flow | 21,345.6B | 21,332.6B | 21,338B | -24.32M | -17.83M | -17.94M | -17.37M | -16.8M | -16.55M | -16.31M | -16.77M | 2.82M | 2.76M | 36.05M | 35.18M | 16.48M | 16.97M |
Free Cash Flow | -29,780.9B | -29,769.4B | -29,778B | -30.23M | -14.02B | -14.02B | -17.4M | -16.82M | -16.54M | -16.29M | -16.68M | -17.04M | -17.14M | -19.49M | -20.7M | -22.22M | -23.3M |